Literature DB >> 6840160

Antihypertensive effect of diazoxide given intravenously in small repeated doses.

A McNair, F Andreasen, P E Nielsen.   

Abstract

Seven patients with acutely elevated diastolic blood pressure (DBP greater than or equal to 135 mmHg) were treated with repeated injections of diazoxide 1 mg/kg body weight i.v. at 10-min intervals. If the DBP was not reduced to 110 mmHg or less after 5 injections, a dose of 5 mg/kg was given. Serum diazoxide (total and unbound) was determined by high pressure liquid chromatography. In all the patients it was possible to reduce the blood pressure to a satisfactory level (i.e. DBP less than 110 mmHg). The individual plasma diazoxide concentrations necessary to achieve the desired response ranged from 20 to 85 micrograms/ml. A significant correlation was found between the initial venous concentration and the initial reduction in blood pressure (p less than 0.02). A high initial concentration in venous blood was associated with high protein binding ("transport function", p less than 0.05), and so were the elimination half-lives, which ranged from 14.7 to 61.3 h ("depot function", p less than 0.05). It is concluded that the previously recommended therapy of injection of 5 mg/kg as a bolus should be given only to patients who do not respond to small repeated doses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840160     DOI: 10.1007/bf00613809

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Hypertensive crisis.

Authors:  F A Finnerty
Journal:  JAMA       Date:  1974-09-09       Impact factor: 56.272

2.  Intravenous diazoxide for severe hypertension in childhood.

Authors:  P N McLaine; K N Drummond
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

3.  Management of severe hypertension with intravenous injections of diazoxide.

Authors:  W E Miller; R W Gifford; D C Humphrey; D G Vidt
Journal:  Am J Cardiol       Date:  1969-12       Impact factor: 2.778

4.  Protein binding and vascular activity of diazoxide.

Authors:  E M Sellers; J Koch-Weser
Journal:  N Engl J Med       Date:  1969-11-20       Impact factor: 91.245

5.  Mechanism of the antihypertensive effect of diazoxide: in vitro vascular studies in the hypertensive rat.

Authors:  A J Wohl; L M Hausler; R E Roth
Journal:  J Pharmacol Exp Ther       Date:  1968-07       Impact factor: 4.030

6.  Hypotensive sequelae of diazoxide and hydralazine therapy.

Authors:  W L Henrich; R Cronin; P D Miller; R J Anderson
Journal:  JAMA       Date:  1977-01-17       Impact factor: 56.272

7.  The importance of the rapid administration of diazoxide in accelerated hypertension.

Authors:  W J Mroczek; B A Leibel; M Davidov; F A Finnerty
Journal:  N Engl J Med       Date:  1971-09-09       Impact factor: 91.245

8.  Emergency treatment of severe hypertension evaluated in a randomized study. Effect of rest and furosemide and a randomized evaluation of chlorpromazine, dihydralazine and diazoxide. Danish Multicenter Study.

Authors: 
Journal:  Acta Med Scand       Date:  1980

9.  Cerebral complications in the treatment of accelerated hypertension.

Authors:  J G Ledingham; B Rajagopalan
Journal:  Q J Med       Date:  1979-01

10.  The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.

Authors:  F Andreasen; C K Christensen; F K Jakobsen; C E Mogensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-09
View more
  1 in total

1.  ATP-sensitive potassium (K(ATP)) channel openers diazoxide and nicorandil lower intraocular pressure in vivo.

Authors:  Uttio Roy Chowdhury; Bradley H Holman; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-22       Impact factor: 4.799

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.